3PSOLUTION

I.N.N.O.VA.T.E:

INTERNATIONAL NEOADJUVANT IMMUNOTHERAPY ACROSS CANCERS

Naples, Italy
Hotel Palazzo Alabardieri

July,11th -12th 2024

Immune checkpoint blockade (ICB) has revolutionized outcomes for patients with advanced cancers. Building upon this marked success, evaluation of ICB in patients with surgically resectable disease has been pursued across multiple cancer types. In addition to an improvement in operability, improving the anti-tumor immune response, as measured by pathologic response, neoadjuvant immunotherapy continues to demonstrate correlation with improved risk or recurrence across and has resulted in changes in standard of care. Complete pathologic response to neoadjuvant treatment has previously been established a surrogate endpoint in some cancers, but data continue to emerge supporting evaluation of this understanding in the context of neoadjuvant ICB and outcomes associated with pathologic response to immunotherapy is actively being pursued across cancers. Neoadjuvant studies also offer the opportunity for deep translational evaluation of serial tissue collection. Taken together, neoadjuvant treatment serves as powerful drug development platform as it provides the opportunity to leverage translational insights to gain a deeper understanding the outcomes associated with pathologic response as well as insights into mechanisms of immunotherapy response and resistance across multiple cancer types.
Notably, the majority of these clinical advances and translational insights are evaluated within disease groups. Many efforts continue to work towards a convergence and harmonization in pathology standardization, trial design, and data aggregation in order to transcend traditional paradigms and leverage the innovative potential of the neoadjuvant platform in cancer immunotherapy. As immunotherapy and checkpoint inhibitors continue to advance for patients with advanced disease, further evaluation in the neoadjuvant setting plays a critical role contextualizing clinical response with deep pathologic and biomarker evaluation. There is an increasing need to expedite insights and facilitate impact for patients through the evaluation of neoadjuvant immunotherapy across cancers.
In this scenario, the importance of early-stage breast and lung cancer is crucial, as it offers the best chance of successful immunotherapy treatment and improved outcomes. Detecting cancer in its early stages allows for less aggressive treatment options, higher survival rates and a better quality of life for patients. Early detection also reduces the risk of metastasis, which can make treatment more difficult and reduce survival rates.

With this in mind, we seek to organize a global meeting to bring together researchers engaged in neoadjuvant immunotherapy clinical and translational research with the goal of highlighting clinical advances, innovative research approaches, as well as possibilities for collaboration and opportunities to harmonize approaches across cancers. With the unique advantage of immunotherapy, we have the opportunity to advance the field forward in both improving outcomes for patients with surgically resectable disease as well as harnessing the true potential of the neoadjuvant platform for drug development.

The meeting will take place over two days and will consist of invited speakers, and panel discussions. Topics will range from disease specific field overviews, pathology, biomarkers, imaging and patient reported outcomes.

Presidency

Paolo A. Ascierto
Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute IRCCS "Fondazione G. Pascale", Naples, Italy

Christian U. Blank
Department of Medical Oncology and Division of Immunology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Ziekenhuis (NKI); Professor in Cancer Immunotherapy, Leiden University Medical Center (LUMC) , The Netherlands; Professor in Hematology/Oncology, University Clinic Regensburg, Germany

Elizabeth M. Burton
Executive Director, Strategic Translational Research Program Development
The University of Texas MD Anderson Cancer Center, Houston TX, US

Preliminary Scientific Program

**Speakers invited*
***Not included in CME accreditation*

JULY, 11th 2024

9.35 am Opening remarks — ***P. A. Ascierto, C. U. Blank, E. M. Burton***

09:50 am – 11:30 am
I SESSION: Neoadjuvant – Practice changing and Drug Development Platform
Session Chair – *L. Buonaguro, G. Curigliano*

09:50 am	Immunotherapy across cancers, ***P. A. Ascierto***
10:10 am	Neoadjuvant therapy for breast cancer: lessons learned, ***L.A. Emens***
10:40 am	Keynote: Neoadjuvant immunotherapy – practice changing clinical trials in early stage management and moving forward, ***T. Cascone***
11:10 am	Panel discussion: neoadjuvant – practice changing and drug development platform ***L. Buonaguro, G. Curigliano***
11:30 am	Coffee Break**

3P Solution S.r.l. a socio unico.
Sede Operativa: Corso Europa, 13 - 20122 Milano
Sede Legale: Via Borgogna, 2 - 20122 Milano
Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.
Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.
Certificazione CSQA n. 23887
Società soggetta ad attività di direzione e coordinamento esercitata dal socio unico Cencora Inc. (Conshohocken, Pennsylvania, USA)

11:45 am – 01:25 pm
II SESSION: Pathology harmonization and surrogate endpoint
Session Chairs – M. Del Vecchio, G. Ferrara

11:45 am	Neoadjuvant path assessment in melanoma, ***M. T. Tetzlaff***
12:05 am	Rationale for pathologic response assessment: where are we today? ***J. Taube***
12:25 am	Pan-cancer scoring system: updates and lessons learned, ***J. S. Deutsch***
12:45 am	Panel discussion: pathologic response assessment – future directions **M. Del Vecchio, G. Ferrara**

*01:25 pm – 02:20 pm Lunch***

02:20 pm – 04:40 pm
III SESSION: Multi disciplinary management
Session Chairs – *M. Chalabi, J. E. Gershenwald*

02:20 pm	Intralesional studies, ***D. Schadendorf***
02:40 pm	Surgical considerations, ***A. M.M. Eggermont***
03:00pm	Radiation, ***C. Faivre-Finn****
03:20 pm	Neoadjuvant data and staging criteria – the time to act is now, ***J. E. Gershenwald***
03:40 pm	Machine learning and radiomics to personalize immunotherapy, ***J. Wu***
04:00 pm	Panel discussion: multi disciplinary management ***Chairs: M. Chalabi, J. E. Gershenwald*** ***Discussant: L. Benedetto****

04:40 pm – 05:00 pm Closing day 1 - ***P. A. Ascierto, C. U. Blank, E. M. Burton***

JULY, 12th 2024

09:30 am – 12:15 pm
IV SESSION: Cancer specific updates in neoadjuvant immunotherapy
Session Chairs – P. A. Ascierto, E. M. Burton

09:30 am	Breast, ***L.A. Emens****
09:50 am	Lung, ***T. Cascone***
10:10 am	Non melanoma skin, ***N. Gross***
10:30 am	Biomarker-driven neoadjuvant immunotherapy in CRC and the path forward, ***M. Chalabi***

10:50 am Neoadjuvant immunotherapy in melanoma: are we finished yet?, ***G. V. Long***
11:10 am **Focus on:** cancer specific updates in neoadjuvant immunotherapy
C. Trojaniello, M.G. Vitale
11:55 am Panel discussion: cancer specific updates in neoadjuvant immunotherapy
P. A. Ascierto, E. M. Burton

*12:15 pm-01:00 pm Lunch***

01:00 pm – 03:10 pm
V SESSION: Translational insights - biomarkers across cancers
Session Chairs - *J. Haanen, Tbd*

01:00 pm Immune insights and translation back to clinic, ***C. U. Blank***
01:20 pm Gene signature, ***C. U. Blank***
01:40 pm Translational insights from neoadjuvant nivo LAG3, ***H. A. Tawbi***
02:00 pm Neoadjuvant radioimmunotherapy in PDAC ***– W. R. Burns****
02:20 pm **Focus on:** Translational insights - biomarkers across cancers
L. Filippi, A. Nuccio, D.H. Peng*
02:50 pm Panel discussion: translational insights - biomarkers across cancers
J. Haanen, Tbd

03:10 pm Coffee Break**

03:25 pm – 05:15 pm
VI SESSION Where do we go from here? Clinical updates/design
Session Chairs – P. A. Ascierto, C. U. Blank

Summary of key points and opportunities and panel discussion

Pathology considerations, ***J. Taube***
Translational considerations, ***C. U. Blank***
Surgical considerations, ***N. Gross***
Study design, ***E. M. Burton***

05:15 -05:30 pm Closing remarks, ***P. A. Ascierto***

SCIENTIFIC BOARD

Paolo A. Ascierto
Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute IRCCS “Fondazione G. Pascale”, Naples, Italy

Christian U. Blank
Department of Medical Oncology and Division of Immunology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Ziekenhuis (NKI); Professor in Cancer Immunotherapy, Leiden University Medical Center (LUMC) , The Netherlands; Professor in Hematology/Oncology, University Clinic Regensburg, Germany

Elizabeth M. Burton
Executive Director, Strategic Translational Research Program Development
The University of Texas MD Anderson Cancer Center, Houston TX, US

FACULTY

Lucia Benedetto*
Unit of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori - IRCCS - Fondazione “G. Pascale”, Naples, Italy

Luigi Buonaguro
Director Innovative Immunological Models Unit, National Cancer Institute, IRCCS Fondazione “G. Pascale”, Naples, Italy

William R. Burns*
Assistant Professor of Surgery, Johns Hopkins School of Medicine, Baltimore, MD, US

Tina Cascone
Associate Professor and Director of Translational Research Department of Thoracic/Head & Neck Medical Oncology
Regular Faculty Member, Immunology and Cancer Biology Programs
Graduate School of Biomedical Sciences (GSBS)
The University of Texas MD Anderson Cancer Center, Houston, TX, US

Myriam Chalabi
Medical Oncologist, GI cancers, Netherlands Cancer Institute, Amsterdam, The Netherlands

Giuseppe Curigliano
Professore Ordinario di Oncologia Medica, Università di Milano; Responsabile della Divisione Clinica dello Sviluppo Precoce di Farmaci, l’Istituto Europeo di Oncologia, Milano, Italia

3P Solution S.r.l. a socio unico.
Sede Operativa: Corso Europa, 13 - 20122 Milano
Sede Legale: Via Borgogna, 2 - 20122 Milano
Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.
Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma
UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.
Certificazione CSQA n. 23887
Società soggetta ad attività di direzione e coordinamento esercitata dal socio unico Cencora Inc. (Conshohocken, Pennsylvania, USA)

Michele Del Vecchio
Responsabile SS Oncologia Medica Melanomi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Julie S. Deutsch
Assistant Professor Department of Dermatology, Johns Hopkins University, Baltimore, MD, US

Alexander M.M. Eggermont
Chief Scientific Officer, Board of Directors, Princess Máxima Center; Professor of Clinical&Translational Immunotherapy, Utrecht University, Utrecht, The Netherlands

Leisha A. Emens
Professor of Medicine, Director of Translational Immunotherapy for the Women's Cancer Research Center, Co-Leader, Hillman Cancer Immunology/Immunotherapy Program, UPMC Hillman Cancer Center/Magee Women's Hospital, Pittsburgh, PA, US

Corinne Faivre-Finn*
FRCR MD PhD
Professor of Thoracic Radiation Oncology,University of Manchester
Honorary Consultant Clinical Oncologist, The Christie NHS Foundation Trust, Manchester, UK

Gerardo Ferrara
Chief, Anatomic Pathology and Cytopathology Unit, Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale, Naples, Italy

Luca Filippi
Nuclear Medicine Unit, Department of Oncohaematology, Fondazione PTV Policlinico Tor Vergata University Hospital, Rome, Italy

Jeffrey E. Gershenwald
Professor of Cancer Biology, Departments of Surgical Oncology and Cancer Biology, Medical Director, Melanoma and Skin Center, The University of Texas, MD Anderson Cancer Center, Houston, TX, US

Neil D. Gross
Professor, Department of Head and Neck Surgery, Division of Surgery Section Chief, Oropharynx Cancer, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX,US

John B.A.G. Haanen
Head of the Division of Medical Oncology; Leader of the research theme Immunotherapy, Netherlands Cancer Institute, Amsterdam, The Netherlands

Georgina V. Long
Co-medical Director , Chair of Melanoma Medical Oncology and Translational Research presso MIA e Royal North Shore Hospital, Melanoma Institute Australia, The University of Sydney, Wollstonecraft NSW, Australia

3P Solution S.r.l. a socio unico.
Sede Operativa: Corso Europa, 13 - 20122 Milano
Sede Legale: Via Borgogna, 2 - 20122 Milano
Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.
Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma
UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.
Certificazione CSQA n. 23887
Società soggetta ad attività di direzione e coordinamento esercitata dal socio unico Cencora Inc. (Conshohocken, Pennsylvania, USA)

Antonio Nuccio
Department of Medical Oncology, Università Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy

David H. Peng*
Institute Senior Research Scientist, The University of Texas MD Anderson Cancer Center, Houston, TX, US

Dirk Schadendorf
Director & Chair, Department of Dermatology & Director, Comprehensive Cancer Center (Westdeutsches Tumorzentrum), University Hospital, Essen, Germany

Janis Taube
Director, Division of Dermatopathology, Professor of Dermatology, Johns Hopkins University, School of Medicine, Baltimore, MD, US

Hussein A. Tawbi
Professor; Deputy Chair, Department of Melanoma Medical Oncology Co-Director, Andrew M. McDougall Brain Metastasis Clinic & Program; Melanoma Medical Oncology; Investigational Cancer Therapeutics; UT MD Anderson Cancer Center, Houston, TX, US

Michael T. Tetzlaff
Professor of Pathology and Dermatology, Departments of Pathology and Dermatology at The University of California, San Francisco, US

Claudia Trojaniello
Medical Doctor, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy

Maria Grazia Vitale
Medical Manager - SC Oncologia Clinica Sperimentale Melanoma, Immunoterapia e Terapie Innovative, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy

Jia Wu
Department of Imaging Physics, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, US

3P Solution S.r.l. a socio unico.
Sede Operativa: Corso Europa, 13 - 20122 Milano
Sede Legale: Via Borgogna, 2 - 20122 Milano
Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.
Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma
UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.
Certificazione CSQA n. 23887
Società soggetta ad attività di direzione e coordinamento esercitata dal socio unico Cencora Inc. (Conshohocken, Pennsylvania, USA)